Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200, Brest, France; Service de Génétique Médicale et de Biologie de la Reproduction, CHRU Brest, F-29200, Brest, France.
Department of Gastroenterology, Changhai Hospital, The Secondary Military Medical University, Shanghai, China; Shanghai Institute of Pancreatic Diseases, Shanghai, China.
Pancreatology. 2023 Aug;23(5):491-506. doi: 10.1016/j.pan.2023.04.004. Epub 2023 Apr 20.
PRSS1 was the first reported chronic pancreatitis (CP) gene. The existence of both gain-of-function (GoF) and gain-of-proteotoxicity (GoP) pathological PRSS1 variants, together with the fact that PRSS1 variants have been identified in CP subtypes spanning the range from monogenic to multifactorial, has made the classification of PRSS1 variants very challenging.
All currently reported PRSS1 variants (derived primarily from two databases) were manually reviewed with respect to their clinical genetics, functional analysis and population allele frequency. They were classified by variant type and pathological mechanism within the framework of our recently proposed ACMG/AMP guidelines-based seven-category system.
The total number of distinct germline PRSS1 variants included for analysis was 100, comprising 3 copy number variants (CNVs), 12 5' and 3' variants, 19 intronic variants, 5 nonsense variants, 1 frameshift deletion variant, 6 synonymous variants, 1 in-frame duplication, 3 gene conversions and 50 missense variants. Based upon a combination of clinical genetic and functional analysis, population data and in silico analysis, we classified 26 variants (all 3 CNVs, the in-frame duplication, all 3 gene conversions and 19 missense) as "pathogenic", 3 variants (missense) as "likely pathogenic", 5 variants (four missense and one promoter) as "predisposing", 13 variants (all missense) as "unknown significance", 2 variants (missense) as "likely benign", and all remaining 51 variants as "benign".
We describe an expert classification of the 100 PRSS1 variants reported to date. The results have immediate implications for reclassifying many ClinVar-registered PRSS1 variants as well as providing optimal guidelines/standards for reporting PRSS1 variants.
PRSS1 是首个报道的慢性胰腺炎(CP)基因。功能性获得(GoF)和获得毒性保护(GoP)病理性 PRSS1 变体的存在,以及 PRSS1 变体已在从单基因到多因素的 CP 亚型中被鉴定出来的事实,使得 PRSS1 变体的分类极具挑战性。
所有目前报道的 PRSS1 变体(主要源自两个数据库)均通过临床遗传学、功能分析和群体等位基因频率进行手动审查。它们根据我们最近提出的基于 ACMG/AMP 指南的七类系统的变体类型和病理机制进行分类。
纳入分析的独特种系 PRSS1 变体总数为 100 个,包括 3 个拷贝数变异(CNV)、12 个 5' 和 3' 变体、19 个内含子变体、5 个无义变体、1 个移码缺失变体、6 个同义变体、1 个框内重复、3 个基因转换和 50 个错义变体。基于临床遗传和功能分析、群体数据和计算机分析的综合结果,我们将 26 个变体(所有 3 个 CNV、框内重复、所有 3 个基因转换和 19 个错义)归类为“致病性”,3 个变体(错义)归类为“可能致病性”,5 个变体(4 个错义,1 个启动子)归类为“易感性”,13 个变体(全部为错义)归类为“意义不明”,2 个变体(错义)归类为“可能良性”,其余 51 个变体全部归类为“良性”。
我们描述了对迄今为止报道的 100 个 PRSS1 变体的专家分类。该结果立即对重新分类许多 ClinVar 注册的 PRSS1 变体具有影响,并为报告 PRSS1 变体提供了最佳的指南/标准。